Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Last trade$6.15
Day change-$0.10 (-1.60%)
Day range$6.03 – $6.29
Volume274,302
Market cap$354M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$354.12M
Price / earnings
4.05×
Price / book
-0.58×
Price / sales
0.35×
EV / sales
1.6×
EV / EBITDA
6.16×
Profitability
Earnings per share
$1.54
Return on assets
6.92%
Return on equity
-14.28%
Dividend yield
7.68%
Liquidity and leverage
Debt / equity
-2.43×
Current ratio
1.68×
Quick ratio
1.17×
Cash ratio
0.51×
Cash flow
Price / cash flow
2.03×
Price / free cash flow
2.15×
Free cash flow
$164.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EMBC, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$271.7M
$221.8M
$261.2M
$264M
$295.5M
$259M
$261.9M
$286.1M
Cost of revenue
$118.4M
$94M
$99.5M
$105.5M
$98.4M
$94.9M
$104.8M
$112.3M
Gross profit
$153.3M
$127.8M
$161.7M
$158.5M
$197.1M
$164.1M
$157.1M
$173.8M
Selling, general and administrative
$78.6M
$76.2M
$77.6M
$86.9M
$84.4M
$79.6M
$81.1M
$96.8M
Research and development
$5.6M
$5.4M
$4.6M
$4.6M
$4.4M
$8M
$20.3M
$19.8M
Total operating expenses
$104.6M
$92.8M
$82.2M
$102M
$103.1M
$101.2M
$101.4M
$147.6M
Operating income
$48.7M
$35M
$79.5M
$56.5M
$94M
$62.9M
$55.7M
$26.2M
Interest expense
-$23.9M
-$22.6M
$0
$0
-$26.6M
-$26.7M
$0
$0
Income before taxes
$27.6M
$9.5M
$58.9M
$29M
$72.2M
$35.8M
-$700K
-$7M
Income taxes
$6.5M
$13.6M
$14.8M
$2.6M
$26.7M
$12.3M
-$700K
-$21.6M
Net income
$21.1M
-$4.1M
$44.1M
$26.4M
$45.5M
$23.5M
$0
$14.6M
Net income attributable to common shareholders
$21.1M
-$4.1M
$44.1M
$26.4M
$45.5M
$23.5M
$0
$14.6M
EBITDA
$67.1M
$45.2M
$89.8M
$61.8M
$111M
$71.9M
$65.1M
$31.9M
Basic earnings per share
$0.36
-$0.07
$0.75
$0.45
$0.78
$0.40
$0.00
$0.25
Diluted earnings per share
$0.36
-$0.07
$0.74
$0.44
$0.78
$0.40
$0.00
$0.24
Recent news
Company coverage with links to the original publishers.
Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.
Embecta Corp. (EMBC) announced that management will participate in investor events at the Wells Fargo 2026 Healthcare Conference on September 9, 2026, in Boston and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026 on September 10, 2026, where they will host fireside chats and one-on-one investor meetings.
Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.
Rosen Law Firm is reminding investors in Zillow Group, Embecta Corp, and GoDaddy Inc. of upcoming lead plaintiff deadlines in securities class actions. The Zillow lawsuit alleges the company made false statements regarding its Redfin agreement and antitrust risks. Investors with losses exceeding $100K are encouraged to contact the firm before the respective deadlines.
Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its third quarter fiscal 2026 financial results on August 7, 2026. The company hosted a conference call and webcast for analysts and investors to discuss the earnings.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 27, 2026
$0.01
Sep 15, 2026
recurring
May 28, 2026
$0.01
Jun 15, 2026
recurring
Feb 27, 2026
$0.15
Mar 17, 2026
recurring
Dec 5, 2025
$0.15
Dec 18, 2025
recurring
Aug 29, 2025
$0.15
Sep 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.